NewAmsterdam Pharma Company N.V.

SecurityNAMS / NewAmsterdam Pharma Company N.V.
InsiderLouise Frederika Kooij
This page shows the track record and history of Kooij Louise Frederika insider trades in NewAmsterdam Pharma Company N.V.. The SEC defines Insiders as officers, directors, or significant investors (greater than 10% ownership) in a company. It is illegal for insiders to make trades in their companies based on material, non-public information ("MNPI"). This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4.
Insider Purchases - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made by Louise Frederika Kooij in NAMS / NewAmsterdam Pharma Company N.V.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

NAMS / NewAmsterdam Pharma Company N.V. Insider Trades
Insider Sales - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made by Louise Frederika Kooij in NAMS / NewAmsterdam Pharma Company N.V.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
2025-09-03 18,073 25.0900 18,073 25.0900 453,452 0 24.8800 -3,795 -0.84
2025-08-25 8,269 24.8600 8,269 24.8600 205,567
2025-03-04 150,000 20.3700 150,000 20.3700 3,055,500
2024-10-01 45,000 15.7200 45,000 15.7200 707,400

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

NAMS / NewAmsterdam Pharma Company N.V. Insider Trades
Insider Transaction History
File
Date
Trade
Date
Form Insider Ticker Security Title Code 10b5-1 Direct Exercise
Price
Unit
Price
Units
Changed
Value
Changed (1K)
Remaining
Options
Remaining
Shares
2025-09-05 2025-09-03 4 Kooij Louise Frederika NAMS Ordinary Shares S - Sale D 25.0900 -18,073 -453 15,000
2025-09-04 2025-09-02 4 Kooij Louise Frederika NAMS Ordinary Shares M - Exercise D 18,073 33,073
2025-08-27 2025-08-25 4 Kooij Louise Frederika NAMS Ordinary Shares S - Sale D 24.8600 -8,269 -206 15,000
2025-03-28 2025-03-26 4 Kooij Louise Frederika NAMS Ordinary Shares M - Exercise D 8,269 23,269
2025-03-05 2025-03-04 4 Kooij Louise Frederika NAMS Ordinary Shares S - Sale D 20.3700 -150,000 -3,056 15,000
2025-03-05 2025-03-04 4 Kooij Louise Frederika NAMS Ordinary Shares M - Exercise D 150,000 165,000
2025-01-07 2025-01-07 4 Kooij Louise Frederika NAMS Ordinary Shares A - Award D 15,000 15,000
2024-10-01 2024-10-01 4 Kooij Louise Frederika NAMS Ordinary Shares S - Sale D 15.7200 -45,000 -707 0
2024-10-01 2024-09-27 4 Kooij Louise Frederika NAMS Ordinary Shares M - Exercise D 45,000 45,000
P
Pasaran terbuka atau pembelian persendirian sekuriti bukan derivatif atau derivatif
S
Pasaran terbuka atau jualan persendirian sekuriti bukan derivatif atau derivatif
A
Pemberian, penganugerahan atau pemerolehan lain sekuriti daripada syarikat (seperti opsyen)
C
Penukaran derivatif
D
Penjualan atau pemindahan sekuriti kembali kepada syarikat
F
Pembayaran harga pelaksanaan atau liabiliti cukai menggunakan sebahagian daripada sekuriti yang diterima daripada syarikat
G
Hadiah sekuriti oleh atau kepada orang dalam
K
Swap ekuiti dan urus niaga lindung nilai yang serupa
M
Pelaksanaan atau penukaran sekuriti derivatif yang diterima daripada syarikat (seperti opsyen)
V
Transaksi dilaporkan secara sukarela pada Borang 4
J
Lain-lain (disertai dengan nota kaki yang menerangkan transaksi)